All News
ICYMI: Combination treatments in Psoriatic Arthritis
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.
Read Article
ICYMI: TNF Inhibitor Drug-Induced Lupus
A study from the FDA's adverse event reporting system (FAERS or Medwatch) database identified cases of drug induced systemic lupus erythematosus (SLE) in patients receiving tumor necrosis factor-α (TNF-α) inhibitors - a paradoxical reaction to common antiinflammatory biologic agents.
Read Article
ICYMI: Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more comorbidity, smoking and corticosteroid use.
Read Article
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5
Dr. John Cush RheumNow ( View Tweet)
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 in numbers
💫5125 abstracts submitted from 95 countries
💫177 scientific sessions
💫350 speakers from 45 nations
💫Balanced gender split of speakers & chairpersons
💫Fresh sessions format
💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
Dr. John Cush RheumNow ( View Tweet)
Glucocorticoid Tapering in SLE
Dr. Yuz Yusof discusses abstract POS1224 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/oI992YLvnB https://t.co/mPmMxcpMey
Dr. John Cush RheumNow ( View Tweet)
GLP 1 Receptor Agonists in axSpA
Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT
Dr. John Cush RheumNow ( View Tweet)
Rituximab - Super Responders Exist in SLE
Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/LkYzMtsErn https://t.co/awRhQmbhoT
Dr. John Cush RheumNow ( View Tweet)
Rheumatology RoundUp: EULAR 2025
https://t.co/csWNjWyIg7 https://t.co/B6AvK1zBqX
Dr. John Cush RheumNow ( View Tweet)
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.
https://t.co/zt0OxwQ2BO https://t.co/eFqHwROQOj
Dr. John Cush RheumNow ( View Tweet)
New IL-17 Inhibition New Molecular Constructs
Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/zz4NRITsRN https://t.co/FrUbmsjxxB
Dr. John Cush RheumNow ( View Tweet)
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n
Dr. John Cush RheumNow ( View Tweet)
HLA-B27 Testing in Practice
A single center study shows HLA-B27 testing is often performed by both by rheumatologists and nonrheumatologists for a wide array of reasons and often along with other serologic tests. Optimal use of HLA-B27 testing has yet to be defined. https://t.co/oq7GNhzwZd
Dr. John Cush RheumNow ( View Tweet)
ARD's Impact Factor
The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc
Dr. John Cush RheumNow ( View Tweet)
JAMA Clinical Challenge - 34-yoF with Forearm Pain and Stiffness. 1 yr of progressive skin tightening over forearms, tibia, LOM of fingers & elbows. Denied DM, Raynauds. Worse after tennis, better w/ steroids. Increased ANA, eosinophils, CRP, aldolase - your Dx? https://t.co/5VrE4OpZ4N
Dr. John Cush RheumNow ( View Tweet)
Pregnancy in SLE: Risks Extend Beyond Clinical Concerns
Pregnancy in patients with systemic lupus erythematosus (SLE) continues to carry significantly elevated risks, with maternal mortality rates nearly five times higher than in the general population.
https://t.co/3G7Eftt0Kg https://t.co/X3SUl6FTHO
Dr. John Cush RheumNow ( View Tweet)
TONIX pharm presented two phase 3 RCTs at #EULAR2025 demonstrating efficacy of sublingual cylcobenzaprine at bedtime in w/ significant reductions in Fibromyalgia pain scores. TNX-102 SL could be the 1st new FM drug to be FDA approved in >15 yrs. PDUFA (decision) date is 8.15.25. https://t.co/XNd8uYLQsJ
Dr. John Cush RheumNow ( View Tweet)
Upcoming Lupus Nephritis Pipeline
1. Gazyva (obinutuzumab) – due for FDA/EMA decision
2. Saphnelo IV (anifrolumab) – now in Phase III (new indication for LN
3. Ianalumab SC (Dual-action B-cell inhibitor) – now in Phase III https://t.co/mTInV8JXzq https://t.co/jEv2uvhkqK
Dr. John Cush RheumNow ( View Tweet)
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Links:
Dr. John Cush RheumNow ( View Tweet)